250 related articles for article (PubMed ID: 16083344)
21. Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention.
Ganai SA
Curr Drug Targets; 2018; 19(6):593-601. PubMed ID: 27231104
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitors for cancer therapy.
Kim TY; Bang YJ; Robertson KD
Epigenetics; 2006; 1(1):14-23. PubMed ID: 17998811
[TBL] [Abstract][Full Text] [Related]
23. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
Noureen N; Rashid H; Kalsoom S
Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
[TBL] [Abstract][Full Text] [Related]
24. Current evidence for histone deacetylase inhibitors in pancreatic cancer.
Koutsounas I; Giaginis C; Patsouris E; Theocharis S
World J Gastroenterol; 2013 Feb; 19(6):813-28. PubMed ID: 23430136
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.
Bose P; Dai Y; Grant S
Pharmacol Ther; 2014 Sep; 143(3):323-36. PubMed ID: 24769080
[TBL] [Abstract][Full Text] [Related]
26. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Jazirehi AR
Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases.
Qiu X; Xiao X; Li N; Li Y
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jan; 72():60-72. PubMed ID: 27614213
[TBL] [Abstract][Full Text] [Related]
28. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitors: overview and perspectives.
Dokmanovic M; Clarke C; Marks PA
Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399
[TBL] [Abstract][Full Text] [Related]
30. Sensitization of tumor cells by targeting histone deacetylases.
Perego P; Zuco V; Gatti L; Zunino F
Biochem Pharmacol; 2012 Apr; 83(8):987-94. PubMed ID: 22120677
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitors: biology and mechanism of action.
Mehnert JM; Kelly WK
Cancer J; 2007; 13(1):23-9. PubMed ID: 17464243
[TBL] [Abstract][Full Text] [Related]
32. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
Li Y; Seto E
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
[TBL] [Abstract][Full Text] [Related]
33. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Gao N; Dai Y; Rahmani M; Dent P; Grant S
Mol Pharmacol; 2004 Oct; 66(4):956-63. PubMed ID: 15235103
[TBL] [Abstract][Full Text] [Related]
34. [Histone deacetylase inhibitors: highlight on epigenetic regulation].
Pécuchet N; Cluzeau T; Thibault C; Mounier N; Vignot S
Bull Cancer; 2010 Aug; 97(8):917-35. PubMed ID: 20483706
[TBL] [Abstract][Full Text] [Related]
35. New Insights into the Role of Histone Deacetylases as Coactivators of Inflammatory Gene Expression.
Schmitz ML; de la Vega L
Antioxid Redox Signal; 2015 Jul; 23(1):85-98. PubMed ID: 24359078
[TBL] [Abstract][Full Text] [Related]
36. Anticancer activities of histone deacetylase inhibitors.
Bolden JE; Peart MJ; Johnstone RW
Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
[TBL] [Abstract][Full Text] [Related]
37. Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer.
Kollar J; Frecer V
Curr Pharm Des; 2015; 21(11):1472-502. PubMed ID: 25382430
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
39. Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers.
Sanaei M; Kavoosi F
Adv Biomed Res; 2019; 8():63. PubMed ID: 31737580
[TBL] [Abstract][Full Text] [Related]
40. Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.
Amin SA; Adhikari N; Jha T
Pharmacol Res; 2018 May; 131():128-142. PubMed ID: 29514055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]